How should an elevated intact parathyroid hormone level of approximately 93 pg/mL be treated?

Treatment of Elevated Intact PTH of 93 pg/mL

The approach to treating an intact PTH of 93 pg/mL depends entirely on the clinical context: measure serum calcium, phosphorus, vitamin D (25-OH), and assess kidney function to determine if this represents primary hyperparathyroidism, secondary hyperparathyroidism, or normocalcemic primary hyperparathyroidism.

Initial Diagnostic Algorithm

Before treating, you must categorize the type of hyperparathyroidism:

1. If Serum Calcium is Elevated (Hypercalcemic Primary Hyperparathyroidism)

Surgery is the definitive treatment if any of the following criteria are present 1, 2:

• Bone fracture or T-score ≤ -2.5 SD on any site
• Kidney stones, nephrocalcinosis, or history of renal colic
• eGFR < 60 mL/min/1.73 m²
• 24-hour urine calcium > 250 mg/day (women) or > 300 mg/day (men)
• Serum calcium > 10 mg/L (0.25 mmol/L) above upper normal limit
• Age < 50 years (consider up to age 70 based on life expectancy)

If surgery is refused or contraindicated, consider pharmacological treatment with calcimimetics (cinacalcet) or bisphosphonates 2.

2. If Serum Calcium is Normal (Evaluate for Secondary vs. Normocalcemic Primary Hyperparathyroidism)

First, systematically exclude all causes of secondary hyperparathyroidism 3, 4, 5, 6:

Check and Correct:

• Vitamin D deficiency: If 25-OH vitamin D < 30 ng/mL, supplement with ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) 3, 7

  • Dosing: 50,000 IU weekly for 8-12 weeks, then maintenance
  • Recheck PTH after repletion (typically 3 months)

• Hypocalcemia: If corrected calcium < 8.4 mg/dL, supplement with calcium carbonate 7

  • Target: 1-2 g elemental calcium daily in divided doses

• Hyperphosphatemia: If present, restrict dietary phosphate and consider phosphate binders 3

• Kidney function: If eGFR < 60 mL/min/1.73 m², this represents CKD-related secondary hyperparathyroidism 3

For CKD-Related Secondary Hyperparathyroidism:

CKD Stage 3 (eGFR 30-59):

• If PTH > 70 pg/mL despite correcting vitamin D and phosphorus 7:
  • Restrict dietary phosphate
  • If ineffective, start calcitriol 0.25 mcg daily or alfacalcidol 0.5 mcg daily
  • Monitor calcium and phosphorus monthly initially

CKD Stage 4 (eGFR 15-29):

• If PTH > 110 pg/mL despite corrections 7:
  • Start active vitamin D (calcitriol or alfacalcidol)
  • Only if calcium < 9.5 mg/dL and phosphorus < 4.6 mg/dL

CKD Stage 5 (dialysis):

• If PTH > 300 pg/mL 7:
  • Calcitriol, alfacalcidol, paricalcitol, or doxercalciferol
  • Target PTH: 150-300 pg/mL
  • Consider calcimimetics if vitamin D therapy causes hypercalcemia/hyperphosphatemia 8

3. Normocalcemic Primary Hyperparathyroidism (NPHPT)

This diagnosis should only be made after rigorous exclusion of all secondary causes 5, 6. NPHPT requires:

• Consistently normal total AND ionized calcium on multiple measurements over 3-6 months
• Elevated PTH on at least 2 occasions
• Complete exclusion of vitamin D deficiency, medications, and other causes of secondary hyperparathyroidism

Management approach:

• If symptomatic (kidney stones, osteoporosis with T-score ≤ -2.5, fractures): Consider surgery 2
• If asymptomatic: Conservative monitoring is reasonable, as progression is not universal 6
• Surgery should be approached conservatively in NPHPT compared to hypercalcemic PHPT 6

Common Pitfalls to Avoid

1. Do not diagnose primary hyperparathyroidism without measuring serum calcium - PTH elevation alone is insufficient
2. Do not overlook vitamin D deficiency - this is the most common reversible cause of elevated PTH 3, 4
3. Do not rush to surgery in normocalcemic patients - ensure thorough exclusion of secondary causes first 6
4. Do not use calcimimetics as first-line in CKD - they do not reduce mortality and cause significant hypocalcemia and nausea 8
5. Do not start active vitamin D in CKD without checking calcium and phosphorus - risk of vascular calcification 3

Medication Considerations

Review current medications that can elevate PTH:

• Lithium
• Thiazide diuretics
• Loop diuretics (causing hypercalciuria)
• Proton pump inhibitors (reducing calcium absorption)

Monitoring Strategy

After initiating treatment:

• Vitamin D supplementation: Recheck 25-OH vitamin D, calcium, phosphorus, and PTH at 3 months
• Active vitamin D in CKD: Check calcium and phosphorus every 2 weeks for 1 month, then monthly; PTH every 3 months 7
• Post-surgical: Monitor for hungry bone syndrome with calcium every 4-6 hours initially 7